GPRC5D may be a promising therapeutic pathway in the treatment of those with relapsed/refractory multiple myeloma, says Susan Bal, MD.
Susan Bal, MD
Advertisement
Articles by Susan Bal, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
Classifying High-Risk Patients With NDMM
4
Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva
5
